These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10683072)

  • 1. Sustained ventricular tachycardia and its successful prophylaxis during high-dose bolus interleukin-2 therapy for metastatic renal cell carcinoma.
    Oleksowicz L; Escott P; Leichman GC; Spangenthal E
    Am J Clin Oncol; 2000 Feb; 23(1):34-6. PubMed ID: 10683072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma.
    Dutcher J
    Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):3. PubMed ID: 12469933
    [No Abstract]   [Full Text] [Related]  

  • 3. Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.
    Dutcher JP
    Oncology (Williston Park); 2002 Nov; 16(11 Suppl 13):4-10. PubMed ID: 12469934
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
    Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-2 therapy of metastatic renal cell carcinoma: update of phase III trials.
    McDermott DF; Regan MM; Atkins MB
    Clin Genitourin Cancer; 2006 Sep; 5(2):114-9. PubMed ID: 17026799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recurring cutaneous eruption in a patient with metastatic renal cell carcinoma being treated with high-dose interleukin 2.
    O'Reilly F; Feldman E; Yang J; Hwu P; Turner ML
    J Am Acad Dermatol; 2003 Apr; 48(4):602-4. PubMed ID: 12664026
    [No Abstract]   [Full Text] [Related]  

  • 7. Long-term efficacy of d/l sotalol in patients with sustained ventricular tachycardia refractory to class I antiarrhythmic drugs.
    Kühlkamp V; Mermi J; Mewis C; Braun U; Seipel L
    Eur Heart J; 1995 Nov; 16(11):1625-31. PubMed ID: 8881857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
    McDermott DF; Atkins MB
    Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer.
    Heinzer H; Huland E; Huland H
    World J Urol; 2001 Apr; 19(2):111-9. PubMed ID: 11374313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
    Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of sotalol on RR interval variability during induced ventricular tachycardia.
    Yli-Mäyry S; García-Alberola A; Haverkamp W; Hindricks G; Martínez-Rubio A; Borggrefe M; Breithardt G
    Am J Cardiol; 1996 Aug; 78(3):372-6. PubMed ID: 8759826
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response of papillary renal cell carcinoma in a solitary kidney to high dose interleukin therapy.
    Diner EK; Linehan M; Walther M
    Int J Urol; 2005 Nov; 12(11):996-7. PubMed ID: 16351658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias.
    Kühlkamp V; Mermi J; Mewis C; Seipel L
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):373-81. PubMed ID: 9125676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Two cases of renal cell carcinoma with ascites after interleukin-2 therapy].
    Kobori G; Maegawa M; Ushida H; Maekawa S; Inoue K; Kaneko Y; Ohmori K; Nishimura K
    Hinyokika Kiyo; 2002 Jul; 48(7):455-7. PubMed ID: 12229188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute generalized exanthematous pustulosis in a patient receiving high-dose recombinant interleukin-2.
    Gunawardane ND; Vaghani SP; Kuzel TM; Cotliar JA
    J Am Acad Dermatol; 2013 Oct; 69(4):e183-4. PubMed ID: 24034391
    [No Abstract]   [Full Text] [Related]  

  • 16. Contemporary trends in high-dose interleukin-2 use for metastatic renal cell carcinoma in the United States.
    Allard CB; Gelpi-Hammerschmidt F; Harshman LC; Choueiri TK; Faiena I; Modi P; Chung BI; Tinay I; Singer EA; Chang SL
    Urol Oncol; 2015 Nov; 33(11):496.e11-6. PubMed ID: 26210683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin 2 in cancer therapy.
    Antony GK; Dudek AZ
    Curr Med Chem; 2010; 17(29):3297-302. PubMed ID: 20712575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Regional immunotherapy of metastatic renal cell carcinoma].
    Heinzer H; Huland E; Huland H
    Urologe A; 2002 May; 41(3):239-48. PubMed ID: 12132273
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can outpatient interleukin-2 and interferon replace high-dose interleukin-2 for metastatic renal cell carcinoma?
    Vieweg J
    Nat Clin Pract Oncol; 2005 Apr; 2(4):192-3. PubMed ID: 16264932
    [No Abstract]   [Full Text] [Related]  

  • 20. Use of interleukin-2 in advanced renal carcinoma: meta-analysis and review of the literature.
    Malaguarnera M; Ferlito L; Gulizia G; Di Fazio I; Pistone G
    Eur J Clin Pharmacol; 2001 Jul; 57(4):267-73. PubMed ID: 11549203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.